XML 39 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 11 Months Ended
Nov. 15, 2016
Aug. 31, 2017
Jun. 30, 2017
Nov. 30, 2016
Jul. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
May 21, 2017
Dec. 31, 2016
Common stock, issued           10,021,220   10,021,220   10,021,220   8,977,138
Reserve stock split description (5,839,283 shares after adjustment for the Company’s 1 for 10 reverse stock split in August 2017)                      
Reserve stock split shares 5,839,283                      
Warrants to purchase shares of common stock                     60,127  
Purchase price of reserve merger consideration               $ 375,000      
Goodwill           $ 3,502,829   3,502,829   $ 3,502,829   $ 3,558,076
Fair value of the assets acquired               620,000        
Intangible asset           2,679,235   2,679,235   2,679,235    
Accumulated amortization of intangible assets           376,831   376,831   376,831    
Amortization           $ 123,038 $ 327,642      
Chief Commercial Officer [Member]                        
Number of restricted shares of common stock     60,000                  
2014 Long-Term Incentive Plan [Member] | Chief Commercial Officer [Member]                        
Number of restricted shares of common stock               60,000        
IthenaPharma Inc [Member]                        
Common stock, issued 58,392,828                      
Reserve stock split description   retroactively adjusted for the 1 for 10 reverse stock split                    
Ownership percentage of issued and outstanding shares 65.00%                      
Warrants to purchase shares of common stock 30,000                      
Maximum percentage of subsequent to the merger 50.00%                      
Purchase price of reserve merger consideration               $ 3,700,000        
Estimated purchase allocation goodwill valuation               $ 55,246   $ 1,238,000    
Novosom Verwaltungs GmbH [Member]                        
Common stock issued during period shares 150,000                      
Novosom Verwaltungs GmbH [Member] | July 2010 Asset Purchase Agreement [Member]                        
Common stock issued during period, value         $ 15,000              
Novosom Verwaltungs GmbH [Member] | July 2016 License Agreement [Member]                        
Common stock issued during period shares       11,905                
Common stock issued during period, value       $ 15,000                
Symplmed Pharmaceuticals LLC [Member] | Purchase Agreement [Member]                        
Purchase consideration     $ 620,000                  
Payment to acquire business     400,000                  
Liabilities assumed     $ 320,000